Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
archives
»
Monthly Archive
» March 2012
March 2012
Buy, Sell, or Hold: Exelixis
Buy, Sell, or Hold: Exelixis
Motley Fool
cabozantinib
prostate cancer
Exelixis
Is Johnson & Johnson A Strong Buy Candidate?
Is Johnson & Johnson A Strong Buy Candidate?
Seeking Alpha
JNJ
Positive Vote for Glaxo's Votrient
Positive Vote for Glaxo's Votrient
Yahoo/Zacks
GSK
Votrient
sarcoma
Sanofi to Acquire Pluromed
Sanofi to Acquire Pluromed
Yahoo/Zacks
Sanofi
Pluromed
Affymax rises after analyst sets 'Outperform' rating, ahead of FDA ruling on anemia drug
Affymax rises after analyst sets 'Outperform' rating, ahead of FDA ruling on anemia drug
Yahoo/AP
peginesatide
anemia
Affymax
Cancer Cures: ASCO Stocks to Give Your Portfolio a Boost
Cancer Cures: ASCO Stocks to Give Your Portfolio a Boost
Motley Fool
Celldex
Arqule
JNJ
Ariad Pharmaceuticals
Aveo Pharmaceutical
Orphan Drug Status for Lexicon Drug
Orphan Drug Status for Lexicon Drug
Yahoo/Zacks
Lexicon Pharmaceuticals
LX1032
carcinoid syndrome
Clovis Oncology plans $75 million stock offering
Clovis Oncology plans $75 million stock offering
Yahoo/AP
Clovis Oncology
Targacept and Incyte Corporation -- Strong Performers in Strengthening Biotechnology Industry
Targacept and Incyte Corporation -- Strong Performers in Strengthening Biotechnology Industry
Yahoo/MarketWire
Targacept
Incyte
Neutral Stance for Onyx Pharma
Neutral Stance for Onyx Pharma
Yahoo/Zacks
ONYX Pharmaceuticals
Pages
« first
‹ previous
…
7
8
9
10
11
12
13
14
15
…
next ›
last »